Nabriva Appoints Elyse Seltzer MD As Chief Medical Officer

Dr William Prince appointed to role of Senior Vice President, Clinical Science

Vienna / Philadelphia, 21 May 2015: Nabriva Therapeutics AG, a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced the appointment of Elyse Seltzer, MD, as Chief Medical Officer. Dr Seltzer assumes the role from Dr William Prince, who will transition to Senior Vice President, Clinical Science.

Based in Philadelphia, Dr Seltzer will supervise medical and regulatory aspects of clinical development and medical affairs for Nabriva and contribute to the company's clinical development strategy. She will work closely with Dr Steven Gelone, the recently appointed Chief Development Officer at Nabriva, as well as the clinical operations team, to execute Nabriva's clinical development program, including the planned Phase 3 clinical trials of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP). Dr Prince will be responsible for the Phase 1 and scientific programs required to support the lefamulin development program for CABP and additional indications.

Dr Colin Broom, Chief Executive Officer of Nabriva, commented on the appointment: "We are very pleased to welcome Elyse to Nabriva. Her extensive experience in the anti-infective therapeutic area, and in leading international clinical development programs will enable us to efficiently advance our lead product, lefamulin, into late stage development for the treatment of CABP. We have established a world class clinical development leadership team to advance our pipeline with a sense of urgency to address an area of significant medical need."

Elyse Seltzer, newly appointed Chief Medical Officer of Nabriva, added: "I am thrilled to join Nabriva. I am excited to have the opportunity to advance a novel class of antibacterials, particularly given the current and evolving challenges around resistance to currently available antibiotics. I look forward to working with the highly experienced clinical team to fulfil this goal."

Dr Seltzer has a strong track record in clinical development within the pharmaceutical industry. She joins Nabriva from GlaxoSmithKline (GSK), where she was Vice President of Global Clinical Sciences and Operations. Prior to joining GSK, Dr Seltzer was Chief Medical Officer at Tengion, a regenerative medicine company. She has also held roles at Centocor and Vicuron, where she led the dalbavancin clinical development program. Dr Seltzer began her industry career in Anti-Infectives Clinical Research and Development at SmithKline Beecham (now GSK). Before joining the pharmaceutical industry, she practiced clinical Infectious Diseases medicine.

Dr Seltzer holds an MD in Medicine from the New York University School of Medicine. She completed her Internal Medicine training at the University of Pennsylvania Medical Center, and her Infectious Diseases training at Yale New Haven Hospital.

For further information, please contact:
Nabriva Therapeutics AG
Dr Colin Broom, Chief Executive Officer
Tel: +43 (0)1 740 930
Email: [email protected]

Hume Brophy
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 2034405654
Email: [email protected]

Notes to editors

About Nabriva Therapeutics AG

Nabriva Therapeutics is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics.

Nabriva's lead pleuromutilin product candidate, lefamulin, is prepared to enter two international Phase 3 clinical trials for the treatment of community-acquired bacterial pneumonia (CABP). Nabriva believes that lefamulin is well suited for use as a first-line empiric monotherapy for the treatment of CABP because of its novel mechanism of action, spectrum of activity, including against multi-drug resistant pathogens, achievement of substantial drug concentrations in lung tissue and fluids, availability as both an intravenous (IV) and oral formulation and favorable safety and tolerability profile. The U.S. Food and Drug Administration (FDA) has designated the IV formulation of lefamulin as a qualified infectious disease product (QIDP) and granted fast track designation to this formulation of lefamulin.

Additional potential opportunities for lefamulin include use in pediatric patients and for the treatment of ventilator-associated bacterial pneumonia (VABP), hospital-acquired bacterial pneumonia (HABP), acute bacterial skin and skin structure infections (ABSSSI), sexually transmitted infections (STIs), osteomyelitis and prosthetic joint infections.

Nabriva has also identified a topical pleuromutilin product candidate, BC-7013, which has completed a Phase 1 clinical trial, and has an ongoing preclinical research program focused on evaluating pleuromutilin compounds with enhanced activity against Gram-negative bacteria, referred to as extended-spectrum pleuromutilins (ESPs).

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.